NICE nods through Alexion's Soliris despite expense

NICE, the heath technology appraisal (HTA) institute for England and Wales, has given the green light to Alexion's expensive orphan drug product, Soliris (eculizumab), despite lingering reservations about how much it will cost the NHS.